Metabolic Dysfunction-Associated Steatohepatitis

Disease State Hub

FDA Alerts

FDA Alert

FDA Approves First Treatment for Adults With MASH, Serious Liver Disease

03/21/2024

Anthony Calabro, MA

The FDA approved resmetirom for the treatment of adults with metabolic dysfunction-associated steatohepatitis with moderate-to-advanced liver fibrosis.

03/21/2024

Research Summaries

FDA Alert

FDA Approves First Treatment for Adults With MASH, Serious Liver Disease

03/21/2024

Anthony Calabro, MA

The FDA approved resmetirom for the treatment of adults with metabolic dysfunction-associated steatohepatitis with moderate-to-advanced liver fibrosis.

03/21/2024

Research Summary

Guideline Update from the American Diabetes Association for the Detection, Management of Patients With Diabetes, Nonalcoholic Fatty Liver Disease

06/28/2023

Based on recent scientific knowledge, the American Diabetes Association (ADA) released a set of updates including recommendations for the detection and management of nonalcoholic fatty liver disease in...

06/28/2023

Treatment

Treatment Options for Patients With NAFLD, NASH

12/08/2020

Identifying treatment options for patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis was among the key topics at the American Association for the Study of Liver Diseases session...

12/08/2020

Hepatology

NAFLD, NASH Is Becoming More Prevalent Worldwide

07/01/2020

Nonalcoholic steatohepatitis is a potentially progressive form of nonalcoholic fatty liver disease. Recent research, which was discussed at the 21st Annual Harvard Nutrition and Obesity Symposium on NAFLD,...

07/01/2020

Liver Disease

NASH in HIV: An All-Too-Common Comorbidity

03/05/2019

During her presentation at CROI 2019, Dr Giada Sebastiani highlighted the prevalence of nonalcoholic steatohepatitis among individuals with HIV and what can be done to prevent progression of disease and...

03/05/2019

October 2024

Current Issue

October 2024

Volume 64

Issue 9